| アブストラクト | PURPOSE: Tolcapone is an efficacious catechol-O-methyltransferase inhibitor for Parkinson's disease (PD). However, safety issues hampered its use in clinical practice. We aimed to provide evidence of safety and efficacy of tolcapone by a systematic literature review to support clinicians' choices in the use of an enlarging PD therapeutic armamentarium. METHODS: We searched PubMed for studies on PD patients treated with tolcapone, documenting the following outcomes: liver enzyme, adverse events (AEs), daily Off-time, levodopa daily dose, unified Parkinson's disease rating scale (UPDRS) part-III, quality of life (QoL), and non-motor symptoms. FAERS and EudraVigilance databases for suspected AEs were interrogated for potential additional cases of hepatotoxicity. RESULTS: Thirty-two studies were included, for a total of 4780 patients treated with tolcapone. Pertaining safety, 0.9% of patients showed liver enzyme elevation > 2. Over 23 years, we found 7 cases of severe liver injury related to tolcapone, 3 of which were fatal. All fatal cases did not follow the guidelines for liver function monitoring. FAERS and EudraVigilance database search yielded 61 reports of suspected liver AEs possibly related to tolcapone. Pertaining efficacy, the median reduction of hours/day spent in Off was 2.1 (range 1-3.2), of levodopa was 108.9 mg (1-251.5), of "On" UPDRS-III was 3.6 points (1.1-6.5). Most studies reported a significant improvement of QoL and non-motor symptoms. CONCLUSION: Literature data showed the absence of relevant safety concerns of tolcapone when strict adherence to hepatic function monitoring is respected. Given its high efficacy on motor fluctuations, tolcapone is probably an underutilized tool in the therapeutic PD armamentarium. |
|---|
| ジャーナル名 | European journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2021/1/9 |
|---|
| 投稿者 | Artusi, Carlo Alberto; Sarro, Lidia; Imbalzano, Gabriele; Fabbri, Margherita; Lopiano, Leonardo |
|---|
| 組織名 | Department of Neuroscience "Rita Levi Montalcini", University of Torino, Via;Cherasco 15, 10126, Torino, Italy. caartusi@gmail.com.;Department of Neurology, Martini Hospital, ASL Citta di Torino, Torino, Italy.;Cherasco 15, 10126, Torino, Italy.;Department of Neurosciences, Clinical Investigation Center CIC 1436, Parkinson;Toulouse Expert Center, NS-Park/FCRIN Network and NeuroToul COEN Center, Toulouse;University Hospital; INSERM; University of Toulouse 3, Toulouse, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33415500/ |
|---|
